AMA CME measure goes nowhere

Share this article:
A proposal by the American Medical Association's Council on Ethical and Judicial Affairs (CEJA) calling for the elimination of commercial sponsorship of medical education was referred back to the council, effectively tabling it for the year.

"It went down in flames," said John Kamp, executive director of the Coalition for Healthcare Communication, adding that a reference committee on Sunday heard vociferous opposition to the measure from representatives of all three primary voting blocks in the AMA House of Delegates -- primary care physicians, state societies and specialty societies.

The AMA's House of Delegates is holding its annual meeting in Chicago through Wednesday.

In a recent report, Industry Support of Professional Education in Medicine, CEJA recommended that industry funding for CME be phased out with exception to technical training on new diagnostic or therapeutic devices and techniques.

Last week, the Accreditation Council for Continuing Medical Education called for a “new paradigm” of commercial support for medical education, with a series of conditions designed to counteract any potential influence on content from industry.    
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...